Recent study have demonstrated that inhibition of JNK and PARP1 can reverse miRNA-363-3p-associated doxorubicin resistance in diffuse large B-cell lymphoma [43]. The gene discussed is MAPK8; the disease is diffuse large B-cell lymphoma.